Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy-Reference-Cited by-同舟云学术

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy

Published:2020-05-28 Issue:9 Volume:8 Page:1678-1681
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clin Case Rep

Author:

Tambaro Francesco Paolo¹²,Khazal Sajad¹^ORCID,Nunez Cesar³,Ragoonanan Dristhi³,Tewari Priti¹,Petropoulos Demetrios¹,Kebriaei Partow⁴,Wierda William George⁵,Mahadeo Kris Michael¹

Affiliation:

1. Department of Pediatrics Pediatric Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA

2. Bone Marrow Transplant Unit Pediatric Oncology Department AORN Santobono Pausilipon Naples Italy

3. Department of Pediatrics The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA

4. Department of Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer Center Houston TexasUSA

5. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TexasUSA

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.2918

Reference16 articles.

1. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome

2. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

3. Shortening the time to manufacture CAR+ T cells with sleeping beauty system supports T‐cell engraftment and anti‐tumor effects in patients with refractory CD19+ tumors;Partow Kebriaei HH;Am Soc Hematol,2017

4. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

5. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults;Critical Reviews in Oncology/Hematology;2024-04

2. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia;Blood Reviews;2023-05

3. Mini‐hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B‐acute lymphoblastic leukemia;Pediatric Blood & Cancer;2022-08-28

4. Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage;Cancers;2022-03-17

5. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review);Journal of Clinical Medicine;2021-06-08